For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > Formulary Search > PAD Profile : Empagliflozin - Chronic Kidney Disease
PAD Profile : Empagliflozin - Chronic Kidney Disease Important
Traffic Light Status
Status 1 of 1.
- Tablets
Guidelines
The following guidelines are available for this indication.
Other Drugs
Other Indications
Additional Documents
No additional documents returned.
Committee Recommendations
The Medicines safety Committee has approved the 'Getting the most from your SGLT2 inhibitor (‘gliflozin’) medicine' PIL which can be adapted for use by services.
The Surrey Heartlands Integrated Care System Area Prescribing Committee (APC) approves empagliflozin as a treatment option for treating chronic kidney disease in line with NICE TA942.
NB: Check NICE guidance for recommended patient cohorts regarding eGFR.
Empagliflozin will be considered GREEN on the traffic light system.
Key considerations:
- If a patient with diabetes were on insulin and on multiple other treatments, a discussion with the specialist diabetes team may be prudent prior to empagliflozin initiation.